Bladder

Metastatic Disease

Prior Treatment with Platinum

First Line

Prior Treatment with Platinum, ICI, or Enfortumab Vedotin

None at this time.

BLDR0042
Open-Label Randomized Controlled Phase III Study of Disisamab Vedotin in Combo w/ Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (HC 1+ and Greater)
PI: Srinivas Sponsor: Seagen Inc.

BLDR0043
Phase Ib/II Basket Study of ACR-368 as Monotherapy & in Combo w/ Gemcitabine in Adult Subjects w/ Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
PI: Khaki Sponsor: Acrivon Therapeutics, Inc.

Prior Chemotherapy or PD-1/PD-L1 ICI Therapy

None at this time.

KEY

Pending
Open for Enrollment
Observational Study
Link
Trial Posting
Extension Study
Immunotherapy

Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu